Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 14

Results For "United-States"

1201 News Found

APL Healthcare’s Unit-IV classified as VAI by the USFDA
News | March 14, 2026

APL Healthcare’s Unit-IV classified as VAI by the USFDA

This inspection is now closed


MetaVia locks down global patent shield for metabolic drug candidate Vanoglipel
Biotech | March 14, 2026

MetaVia locks down global patent shield for metabolic drug candidate Vanoglipel

The protections extend through at least 2035, with the potential for further extensions


Novo Nordisk strikes deal with Hims & Hers, expands access to Ozempic & Wegovy in US
News | March 10, 2026

Novo Nordisk strikes deal with Hims & Hers, expands access to Ozempic & Wegovy in US

Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms


DiaMedica bags Health Canada nod for Phase 2 preeclampsia trial
Clinical Trials | March 09, 2026

DiaMedica bags Health Canada nod for Phase 2 preeclampsia trial

DiaMedica said it plans to launch the trial later in 2026


SEQSTER launches 1-Click DataLake, unlocking real-world health data from 150M+ patients
Digitisation | March 09, 2026

SEQSTER launches 1-Click DataLake, unlocking real-world health data from 150M+ patients

The company says those insights can power advanced analytics and real-world evidence (RWE), helping researchers improve trial design, study feasibility, and recruitment strategies


Alembic enters US branded market with first sales of Pivya UTI treatment
News | March 06, 2026

Alembic enters US branded market with first sales of Pivya UTI treatment

Pivya is Alembic’s first branded pharmaceutica product in the US and is being marketed through Alembic Therapeutics LLC


KIMS Hospitals launches India’s first adaptive deep brain stimulation for Parkinson’s patients
News | March 05, 2026

KIMS Hospitals launches India’s first adaptive deep brain stimulation for Parkinson’s patients

Built on the Percept Platform and enhanced with BrainSense technology, the system can adjust stimulation levels in real time, responding to brain signals without manual intervention